Oncodesign SA
Oncodesign SA Fundamental Analysis
Oncodesign SA (ALONC.PA) shows weak financial fundamentals with a PE ratio of -97.54, profit margin of -2.79%, and ROE of -8.81%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -8.3/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze ALONC.PA's fundamental strength across five key dimensions:
Efficiency Score
WeakALONC.PA struggles to generate sufficient returns from assets.
Valuation Score
ExcellentALONC.PA trades at attractive valuation levels.
Growth Score
ModerateALONC.PA shows steady but slowing expansion.
Financial Health Score
WeakALONC.PA carries high financial risk with limited liquidity.
Profitability Score
WeakALONC.PA struggles to sustain strong margins.
Key Financial Metrics
Is ALONC.PA Expensive or Cheap?
P/E Ratio
ALONC.PA trades at -97.54 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, ALONC.PA's PEG of -0.98 indicates potential undervaluation.
Price to Book
The market values Oncodesign SA at 8.70 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 15.52 times EBITDA. This signals the market has high growth expectations.
How Well Does ALONC.PA Make Money?
Net Profit Margin
For every $100 in sales, Oncodesign SA keeps $-2.79 as profit after all expenses.
Operating Margin
Core operations generate 1.54 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-8.81 in profit for every $100 of shareholder equity.
ROA
Oncodesign SA generates $-1.71 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
FCF Per Share
Each share generates $-0.34 in free cash annually.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-97.54
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.98
vs 25 benchmark
P/B Ratio
Price to book value ratio
8.70
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.00
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
2.32
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.96
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.09
vs 25 benchmark
ROA
Return on assets percentage
-0.02
vs 25 benchmark
ROCE
Return on capital employed
0.04
vs 25 benchmark
How ALONC.PA Stacks Against Its Sector Peers
| Metric | ALONC.PA Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -97.54 | 28.45 | Better (Cheaper) |
| ROE | -8.81% | 763.00% | Weak |
| Net Margin | -2.79% | -45265.00% (disorted) | Weak |
| Debt/Equity | 2.32 | 0.34 | Weak (High Leverage) |
| Current Ratio | 0.96 | 2795.60 | Weak Liquidity |
| ROA | -1.71% | -16588.00% (disorted) | Weak |
ALONC.PA outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Oncodesign SA's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation